MolMed Overview
- Founded
- 1996

- Status
- Acquired/Merged
- Employees
- 223

- Latest Deal Type
- M&A
- Financing Rounds
- 7
- Investments
- 1
MolMed General Information
Description
Molmed SpA is an Italy based medical biotechnology company. It is engaged in research, development and clinical validation of innovative therapies to treat cancer. The company's therapies include TK for blood cancers and NGR-hTNF for solid tumors. Its pipeline includes antitumor therapeutics in clinical and preclinical development.
Contact Information
- Via Olgettina 58
- 20132 Milan
- Italy
MolMed Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore MolMed‘s full profile, request access.
Request a free trialMolMed Comparisons
Industry
00000
000000 0
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMolMed Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Agios | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
000000 000000 | Formerly VC-backed | Amsterdam, Netherlands | 000 | 00000 | 000000&0 | 00000 |
MolMed Patents
MolMed Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
DE-69916829-D1 | Genetically modified fibroblasts and their use | Expired - Fee Related | 08-May-1998 | 0000000000 | |
EP-1084232-B1 | Genetically-modified fibroblasts and the use thereof | Expired - Lifetime | 08-May-1998 | 0000000000 | |
EP-1084232-A1 | Genetically-modified fibroblasts and the use thereof | Granted | 08-May-1998 | 0000000000 | |
AU-4037299-A | Genetically-modified fibroblasts and the use thereof | Abandoned | 08-May-1998 | 0000000000 | |
CA-2331826-A1 | Genetically-modified fibroblasts and the use thereof | Abandoned | 08-May-1998 | C12N5/0658 |
MolMed Executive Team (5)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Riccardo Palmisano MD | Chief Executive Officer | ||
Claudio Bordignon MD | Founder & Chairman |
MolMed Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
0000000 000000000 00 | MolMed | Founder & Chairman | 000 0000 |
MolMed Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMolMed Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore MolMed‘s full profile, request access.
Request a free trialMolMed Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 | 01-Jan-2002 | 0000000000 | Biotechnology |